|
TW321649B
(en)
*
|
1994-11-12 |
1997-12-01 |
Zeneca Ltd |
|
|
GB9424233D0
(en)
*
|
1994-11-30 |
1995-01-18 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9508538D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9508565D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
|
GB9508537D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9508535D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivative
|
|
US5932574A
(en)
*
|
1995-04-27 |
1999-08-03 |
Zeneca Limited |
Quinazoline derivatives
|
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
|
AU719434B2
(en)
|
1996-02-13 |
2000-05-11 |
Astrazeneca Ab |
Quinazoline derivatives as VEGF inhibitors
|
|
GB9603097D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
|
ES2169355T3
(en)
|
1996-03-05 |
2002-07-01 |
Astrazeneca Ab |
DERIVATIVES OF 4-ANILINOQUINAZOLINA.
|
|
DE69710712T3
(en)
|
1996-04-12 |
2010-12-23 |
Warner-Lambert Co. Llc |
REVERSIBLE INHIBITORS OF TYROSINE KINASEN
|
|
GB9607729D0
(en)
*
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
|
US6329380B1
(en)
*
|
1999-06-30 |
2001-12-11 |
Merck & Co., Inc. |
SRC kinase inhibitor compounds
|
|
EP1676845B1
(en)
|
1999-11-05 |
2008-06-11 |
AstraZeneca AB |
New quinazoline derivatives
|
|
UA74803C2
(en)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use
|
|
JP2003519127A
(en)
*
|
1999-12-29 |
2003-06-17 |
ワイス |
Tricyclic protein kinase inhibitors
|
|
US6638929B2
(en)
|
1999-12-29 |
2003-10-28 |
Wyeth |
Tricyclic protein kinase inhibitors
|
|
AU2001293869A1
(en)
*
|
2000-10-11 |
2002-04-22 |
Morphochem Ag |
Butenolide and pentenolide derivatives as kinase inhibitors
|
|
DE60134679D1
(en)
|
2000-10-20 |
2008-08-14 |
Eisai R&D Man Co Ltd |
Nitrogen-containing aromatic heterocycles
|
|
MXPA03005855A
(en)
|
2000-12-29 |
2003-09-10 |
Wyeth Corp |
Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines.
|
|
SV2007000775A
(en)
|
2001-01-05 |
2007-03-15 |
Pfizer |
ANTIBODIES AGAINST THE RECEIVER OF THE SIMILAR TO INSULIN GROWTH FACTOR
|
|
WO2003000194A2
(en)
|
2001-06-21 |
2003-01-03 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
|
AR039067A1
(en)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
ANTIBODIES FOR CD40
|
|
US7078409B2
(en)
|
2002-03-28 |
2006-07-18 |
Beta Pharma, Inc. |
Fused quinazoline derivatives useful as tyrosine kinase inhibitors
|
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
|
CA2494061C
(en)
|
2002-07-31 |
2011-06-14 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
|
AU2003273675A1
(en)
|
2002-10-09 |
2004-05-04 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
|
SI1585743T1
(en)
|
2002-12-19 |
2007-08-31 |
Pfizer |
2-(1h-indazol-6-ylamino)- benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases
|
|
CN103265477B
(en)
|
2003-02-26 |
2017-01-11 |
苏根公司 |
Aminoheteroaryl compounds as protein kinase inhibitors
|
|
US20050026879A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
|
HN2004000285A
(en)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTIBODIES DIRECTED TO c-MET
|
|
ATE412655T1
(en)
|
2003-08-29 |
2008-11-15 |
Pfizer |
THIENOPYRIDINPHENYLACETAMIDE AND DERIVATIVES THEREOF SUITABLE AS NEW ANTIANGIOGENIC AGENTS
|
|
AR045563A1
(en)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
ANTIBODIES DIRECTED TO M-CSF
|
|
JP4303726B2
(en)
|
2003-11-11 |
2009-07-29 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Urea derivative and method for producing the same
|
|
WO2005051919A1
(en)
|
2003-11-26 |
2005-06-09 |
Pfizer Products Inc. |
Aminopyrazole derivatives as gsk-3 inhibitors
|
|
CN101014365B
(en)
|
2004-07-16 |
2011-04-13 |
辉瑞产品公司 |
Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
|
|
CA2577664A1
(en)
*
|
2004-08-20 |
2006-03-02 |
Bayer Pharmaceuticals Corporation |
Novel heterocycles
|
|
PL1786785T3
(en)
|
2004-08-26 |
2010-08-31 |
Pfizer |
Enantiomerically pure aminoheteroaryl compounds as protein kinases
|
|
ES2322175T3
(en)
|
2004-09-17 |
2009-06-17 |
EISAI R&D MANAGEMENT CO., LTD. |
MEDICINAL COMPOSITION WITH IMPROVED STABILITY AND REDUCED GELIFICATION.
|
|
UY29161A1
(en)
|
2004-10-15 |
2006-04-28 |
Bayer Pharmaceuticals Corp |
NEW HETEROCICLOS
|
|
EP1819711B1
(en)
*
|
2004-10-27 |
2010-04-21 |
Bayer Schering Pharma Aktiengesellschaft |
Pyrimidothienoindazoles capable of inhibiting tyrosine kinases of the epidermal growth factor
|
|
WO2006105488A2
(en)
|
2005-03-31 |
2006-10-05 |
Agensys, Inc. |
Antibodies and related molecules that bind to 161p2f10b proteins
|
|
EP2444421A1
(en)
|
2005-04-26 |
2012-04-25 |
Pfizer Inc. |
P-Cadherin antibodies
|
|
US9006240B2
(en)
|
2005-08-02 |
2015-04-14 |
Eisai R&D Management Co., Ltd. |
Method for assay on the effect of vascularization inhibitor
|
|
CN101517068B
(en)
|
2005-09-07 |
2017-02-08 |
安进弗里蒙特公司 |
Human monoclonal antibodies to activin receptor-like kinase-1
|
|
JP5055284B2
(en)
|
2005-09-20 |
2012-10-24 |
オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー |
Biological markers for predicting anti-cancer responses to insulin-like growth factor-1 receptor kinase inhibitors
|
|
MX2008013990A
(en)
|
2006-05-09 |
2009-01-29 |
Pfizer Prod Inc |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof.
|
|
NL2000613C2
(en)
|
2006-05-11 |
2007-11-20 |
Pfizer Prod Inc |
Triazole pyrazine derivatives.
|
|
CA2652442C
(en)
|
2006-05-18 |
2014-12-09 |
Eisai R & D Management Co., Ltd. |
Antitumor agent for thyroid cancer
|
|
EP2065372B1
(en)
|
2006-08-28 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
|
JP5319306B2
(en)
|
2007-01-29 |
2013-10-16 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Composition for treatment of undifferentiated gastric cancer
|
|
EP2851091B1
(en)
|
2007-04-13 |
2017-12-27 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer resistant to ERBB therapeutics
|
|
HRP20130649T1
(en)
|
2007-09-07 |
2013-08-31 |
Agensys, Inc. |
Antibodies and related molecules that bind to 24p4c12 proteins
|
|
CN101848895B
(en)
|
2007-11-09 |
2013-10-23 |
卫材R&D管理有限公司 |
Combined use of angiogenesis inhibitory substance and antitumor platinum complex
|
|
US8466151B2
(en)
|
2007-12-26 |
2013-06-18 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
|
US8802849B2
(en)
|
2008-02-19 |
2014-08-12 |
Vichem Chemie Kutató Kft. |
Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use
|
|
CA2730890C
(en)
|
2008-07-17 |
2018-05-15 |
Critical Outcome Technologies Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
|
JP5836125B2
(en)
|
2008-10-16 |
2015-12-24 |
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
Fully human antibodies against high molecular weight melanoma-related antigens and uses thereof
|
|
WO2010090764A1
(en)
|
2009-02-09 |
2010-08-12 |
Supergen, Inc. |
Pyrrolopyrimidinyl axl kinase inhibitors
|
|
WO2010099139A2
(en)
|
2009-02-25 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
|
JP2012519170A
(en)
|
2009-02-26 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
INSITU method for monitoring EMT status of tumor cells in vivo
|
|
JP2012519281A
(en)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
Methods for identifying mesenchymal tumor cells or agents that inhibit their production
|
|
US20100222381A1
(en)
|
2009-02-27 |
2010-09-02 |
Hariprasad Vankayalapati |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
|
US8465912B2
(en)
|
2009-02-27 |
2013-06-18 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
AU2010285740C1
(en)
|
2009-08-19 |
2016-03-17 |
Eisai R&D Management Co., Ltd. |
Quinoline derivative-containing pharmaceutical composition
|
|
WO2011027249A2
(en)
|
2009-09-01 |
2011-03-10 |
Pfizer Inc. |
Benzimidazole derivatives
|
|
JP5745283B2
(en)
|
2010-02-12 |
2015-07-08 |
ファイザー・インク |
8-Fluoro-2- {4-[(methylamino) methyl] phenyl} -1,3,4,5-tetrahydro-6H-azepino [5,4,3-cd] indol-6-one salts and many Form
|
|
WO2011109584A2
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
AU2011223643A1
(en)
|
2010-03-03 |
2012-06-28 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
EP2552915B1
(en)
|
2010-04-01 |
2017-07-19 |
Critical Outcome Technologies Inc. |
Compounds for the treatment of hiv
|
|
CN104689314B
(en)
|
2010-06-16 |
2018-02-02 |
高等教育联邦系统-匹兹堡大学 |
Antibody of endoplasmin and application thereof
|
|
ES2573515T3
(en)
|
2010-06-25 |
2016-06-08 |
Eisai R&D Management Co., Ltd. |
Anti-tumor agent that uses compounds with combined kinase inhibitory effect
|
|
ES2543151T3
(en)
|
2010-10-20 |
2015-08-17 |
Pfizer Inc |
2-Pyridine derivatives as Smoothened receptor modulators
|
|
WO2012116040A1
(en)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
|
SG10201913982WA
(en)
|
2011-03-04 |
2020-03-30 |
Newgen Therapeutics Inc |
Alkyne Substituted Quinazoline Compound And Methods Of Use
|
|
US10952415B2
(en)
|
2011-03-09 |
2021-03-23 |
Richard G. Pestell |
Prostate cancer cell lines, gene signatures and uses thereof
|
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
|
JP6021805B2
(en)
|
2011-04-18 |
2016-11-09 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Tumor treatment
|
|
ES2724801T3
(en)
|
2011-04-19 |
2019-09-16 |
Pfizer |
Combinations of anti-4-1BB antibodies and ADCC inducing antibodies for cancer treatment
|
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
EP3444363B1
(en)
|
2011-06-03 |
2020-11-25 |
Eisai R&D Management Co., Ltd. |
Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
|
PT3409278T
(en)
|
2011-07-21 |
2020-12-18 |
Sumitomo Dainippon Pharma Oncology Inc |
Heterocyclic protein kinase inhibitors
|
|
CA2847540C
(en)
|
2011-09-22 |
2016-05-17 |
Pfizer Inc. |
Pyrrolopyrimidine and purine derivatives
|
|
WO2013050725A1
(en)
|
2011-10-04 |
2013-04-11 |
King's College London |
Ige anti -hmw-maa antibody
|
|
BR112014011115A2
(en)
|
2011-11-08 |
2017-06-13 |
Pfizer |
Methods for treating inflammatory disorders using anti-csf antibodies
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
WO2013173312A1
(en)
|
2012-05-14 |
2013-11-21 |
Pestell Richard G |
Using modulators of ccr5 for treating cancer
|
|
US9394257B2
(en)
|
2012-10-16 |
2016-07-19 |
Tolero Pharmaceuticals, Inc. |
PKM2 modulators and methods for their use
|
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
|
BR112015009004A8
(en)
|
2012-12-21 |
2021-07-20 |
Eisai R&D Man Co Ltd |
amorphous form of quinoline derivative and method of production thereof
|
|
ES2738493T3
(en)
|
2013-03-14 |
2020-01-23 |
Tolero Pharmaceuticals Inc |
JAK2 and ALK2 inhibitors and methods for their use
|
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
|
US10517861B2
(en)
|
2013-05-14 |
2019-12-31 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
|
WO2015051304A1
(en)
|
2013-10-04 |
2015-04-09 |
Aptose Biosciences Inc. |
Compositions, biomarkers and their use in treatment of cancer
|
|
UA115388C2
(en)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
|
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
|
KR20160149256A
(en)
|
2014-04-30 |
2016-12-27 |
화이자 인코포레이티드 |
Cycloalkyl-linked diheterocycle derivatives
|
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
|
EP3473271B1
(en)
|
2014-07-31 |
2022-07-20 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Human monoclonal antibodies against epha4 and their use
|
|
JP6659554B2
(en)
|
2014-08-28 |
2020-03-04 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
High purity quinoline derivative and method for producing the same
|
|
EP3233829B1
(en)
|
2014-12-18 |
2019-08-14 |
Pfizer Inc |
Pyrimidine and triazine derivatives and their use as axl inhibitors
|
|
LT3263106T
(en)
|
2015-02-25 |
2024-01-10 |
Eisai R&D Management Co., Ltd. |
METHOD OF REDUCING BITTERNESS OF QUINOLINE DERIVATIVES
|
|
AU2015384801B2
(en)
|
2015-03-04 |
2022-01-06 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
|
|
HK1251655A1
(en)
|
2015-04-20 |
2019-02-01 |
Tolero Pharmaceuticals, Inc. |
Predicting response to alvocidib by mitochondrial profiling
|
|
CN107709344B
(en)
|
2015-05-01 |
2022-07-15 |
共晶制药股份有限公司 |
Nucleoside analogs for the treatment of Flaviviridae and cancer
|
|
EP4086264B1
(en)
|
2015-05-18 |
2023-10-25 |
Sumitomo Pharma Oncology, Inc. |
Alvocidib prodrugs having increased bioavailability
|
|
AU2016279474B2
(en)
|
2015-06-16 |
2021-09-09 |
Eisai R&D Management Co., Ltd. |
Anticancer agent
|
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
|
US10568887B2
(en)
|
2015-08-03 |
2020-02-25 |
Tolero Pharmaceuticals, Inc. |
Combination therapies for treatment of cancer
|
|
SG11201801083UA
(en)
|
2015-08-20 |
2018-03-28 |
Eisai R&D Man Co Ltd |
Tumor therapeutic agent
|
|
WO2017096165A1
(en)
|
2015-12-03 |
2017-06-08 |
Agios Pharmaceuticals, Inc. |
Mat2a inhibitors for treating mtap null cancer
|
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
MX2019007332A
(en)
|
2016-12-19 |
2019-11-18 |
Tolero Pharmaceuticals Inc |
Profiling peptides and methods for sensitivity profiling.
|
|
CN110072528B
(en)
|
2017-02-08 |
2022-04-26 |
卫材R&D管理有限公司 |
Pharmaceutical composition for treating tumor
|
|
KR20200013644A
(en)
|
2017-05-16 |
2020-02-07 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
Treatment of Hepatocellular Carcinoma
|
|
JP7196160B2
(en)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
Treatment Regimens for Cancers Insensitive to BCL-2 Inhibitors Using the MCL-1 Inhibitor Albocidib
|
|
WO2019075367A1
(en)
|
2017-10-13 |
2019-04-18 |
Tolero Pharmaceuticals, Inc. |
Pkm2 activators in combination with reactive oxygen species for treatment of cancer
|
|
US11040038B2
(en)
|
2018-07-26 |
2021-06-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
|
|
AU2019391097B2
(en)
|
2018-12-04 |
2025-07-03 |
Sumitomo Pharma America, Inc. |
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
|
NZ778055A
(en)
|
2019-02-12 |
2025-11-28 |
Sumitomo Pharma America Inc |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
JP2022525149A
(en)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド |
Treatment of Acute Myeloid Leukemia (AML) with Venetoclax Failure
|
|
EP3941463A1
(en)
|
2019-03-22 |
2022-01-26 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
|
WO2022143533A1
(en)
*
|
2020-12-30 |
2022-07-07 |
成都百裕制药股份有限公司 |
Quinazoline derivative and use thereof in medicine
|
|
CN115260207A
(en)
*
|
2021-04-30 |
2022-11-01 |
赣江新区博瑞创新医药有限公司 |
Tricyclic compound, pharmaceutical composition and application thereof
|